Technically we develop medicines. Practically we improve conditions for patients.

Ferring's R&D activities are always driven by the same goals: to develop patient-friendly products that treat unmet medical needs in our key therapeutic areas. We focus our R&D efforts on peptide-based drugs and biotechnology derived medicines. Later stage small chemical molecules within our core therapeutic areas are also included in our development portfolio. Investment in development includes the incorporation of state-of-the-art technology to capitalise on the company’s expertise. We also strive to develop drug delivery systems that ensure convenient and efficient administration of our drugs.

  • Reproductive Health
    Reproductive Health

  • Reproductive Health

    Ferring is a world leader in Assisted Reproductive Technology (ART) for fertility treatment. Ferring’s on-going research efforts in this area strive to meet the growing needs of patients as increasing numbers of couples seek help to conceive. Ferring also offers a range of peptide-based medicines to prevent pre-term labour.

    Ferring has developed MENOPUR® (menotropin) and BRAVELLE® (human follicle stimulating hormone) to stimulate the ovaries, DECAPEPTYL® (gonadotropin releasing hormone agonist) to control the timing of ovary stimulation and CHORAGON® (human chorionic gonadatropin) to induce ovulation.

    Research at Ferring into the use of oxytocin antagonists to help manage and prevent pre-term labour, led to the development of TRACTOCILE® (atosiban).

    A novel peptide (barusiban) is in advanced clinical trials to aid implantation support in ART.

    Ferring is using its recombinant DNA technology platform to develop recombinant gonadotropins to complement its human derived gonadotropin franchise. Its principal candidate (human recombinant follicle stimulating hormone) is in Phase III studies.

  • Urology
    Urology

  • Urology

    Ferring is committed to the development of medicines to treat urological disorders such as diabetes insipidus, enuresis and nocturia. Ferring's lead product in this area is MINIRIN® (desmopressin) which effectively treats enuresis in children and nocturia in adults. A vasopressin receptor agonist designed to bring additional treatment benefits in this therapy area is in early stage development.

    For the treatment of patients with advanced prostate cancer, Ferring has launched a 1-month dosing regimen of FIRMAGON® (degarelix), a gonadotropin-releasing hormone (GnRH) receptor antagonist in the US, Europe and through a partner in Japan. We are conducting clinical studies to further demonstrate the benefits of therapy using a (GnRH) receptor antagonist in the treatment of advanced prostate cancer.

  • Gastroenterology
    Gastroenterology

  • Gastroenterology

    Ferring has a strong heritage of educational support, sponsorship and clinical research within Inflammatory Bowel Disease (IBD). A series of developmental initiatives are underway to bring new products in this indication to market.

    A glucagon like peptide-2 receptor (GLP-2) agonist discovered by Ferring with strong potential in gastrointestinal and oncology indications is in early stage development through a partnership.

    We have in-licensed a novel selective IL-6 soluble receptor antagonist from Conaris Research Institute AG, a spin-off of Kiel University. This product is being developed for inflammatory bowel disease (IBD) and other immune disorders. Patient Phase I programme is on-going with Phase II planned for 2015.

    Ferring's key product PENTASA® (mesalazine) is approved for the treatment of IBD including Crohn's disease and ulcerative colitis. Ferring is continuing to develop many different dosage-forms for PENTASA® such as tablets, sachets and suppositories to meet changing patient and physician needs.

    In 2013 Ferring, together with Cosmo Pharmaceuticals SpA, launched budesonide MMX™, which is indicated for use in ulcerative colitis. Ferring’s license from Cosmo Pharmaceuticals does not include the US and Japan.

    The Ferring gastroenterology portfolio also includes bowel preparations - PICOPREP® / PREPOPIK® (sodium picosulphate, magnesium oxide, citric acid) - used to prepare patients for colonoscopy, and GLYPRESSIN® (terlipressin) which is indicated for the treatment of bleeding oesophageal varices. Building on our experience with GLYPRESSIN® Ferring is developing a partial vasopressin-1a receptor agonist for treatment of refractory ascites.

  • Endocrinology
    Endocrinology

  • Endocrinology

    Ferring produces a recombinant human growth hormone (hGH) ZOMACTON® (somatropin) to treat growth failure in children and Turner's syndrome in girls.

    Selepressin, a vasopressin receptor agonist, is in phase II development for vasopressor-dependent septic shock.

    Two phase II trials in septic shock patients have been conducted to date. Interesting data has been observed by the company. In the placebo-controlled trial, selepressin dose-dependently reduced norepinephrine requirements and the need for mechanical ventilation. Selepressin also tended to shorten time to shock resolution and decrease cumulative fluid balance and percent fluid overload.

  • Orthopaedics
    Orthopaedics

  • Orthopaedics

    EUFLEXXA® (1% sodium hyaluronate) was launched in the US and is the platform for our Orthopaedics Therapeutic area. EUFLEXXA® is a high purity hyaluronan, which when injected into the knees of osteoarthritis sufferers restores movement and removes pain.

Headquarters

FERRING INTERNATIONAL CENTER S.A.
CH. DE LA VERGOGNAUSAZ 50
1162 SAINT-PREX
SWITZERLAND

TEL:  +41 58 301 00 00
FAX: +41 58 301 00 10

CONTACT

Global Locator